Theravance Biopharma, Inc. Reports Second Quarter 2018 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Theravance Biopharma (TBPH) Tops Q2 EPS by 44c, Revenues Beat
August 1, 2018 7:11 AM EDTTheravance Biopharma (NASDAQ: TBPH) reported Q2 EPS of ($0.76), $0.44 better than the analyst estimate of ($1.20). Revenue for the quarter came in at $23.75 million versus the consensus estimate of $10.67 million.
Rick E Winningham, Chairman and Chief Executive Officer, commented: "We have made exciting progress... More
